MB

Monroe Biomedical Research at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Monroe Biomedical Research brings 3 presentations to ObesityWeek 2026 in National Harbor. Its sessions report clinical study results for obesity drug candidates. They cover CRB-913 in the CANYON-1 study, subcutaneous VK2735 and cardiometabolic measures in the VENTURE study, and the effects of enicepatide on body composition in adults with overweight or obesity.

OrganizationObesityWeek 2026 Attendance
MB
Monroe Biomedical Research
Monroe, NC
CROs & trial sites
Clinical trial site network that owns its research sites, including the Louisville Metabolic and Atherosclerosis Research Center in Kentucky.
Poster
Sun Nov 15
2:30pm–3:30pm
Poster
Sun Nov 15
2:30pm–3:30pm
Efficacy, Safety, and Tolerability of CRB-913 in the Phase 1b CANYON-1 Study
Interventional and clinical studiesObesity pharmacotherapy and drug development

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Monroe Biomedical Research

Tell us what you sell and we’ll find the people at Monroe Biomedical Research most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction